Live Oak Private Wealth LLC Trims Stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Live Oak Private Wealth LLC decreased its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 7.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 47,986 shares of the medical equipment provider’s stock after selling 3,994 shares during the period. Live Oak Private Wealth LLC’s holdings in Zimmer Biomet were worth $5,069,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of ZBH. Dunhill Financial LLC grew its holdings in Zimmer Biomet by 1,090.0% during the 3rd quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock valued at $26,000 after buying an additional 218 shares in the last quarter. Ashton Thomas Securities LLC bought a new stake in Zimmer Biomet in the 3rd quarter valued at $28,000. Brooklyn Investment Group purchased a new stake in Zimmer Biomet in the 3rd quarter worth $35,000. R Squared Ltd bought a new position in shares of Zimmer Biomet during the 4th quarter valued at about $63,000. Finally, Mather Group LLC. grew its position in shares of Zimmer Biomet by 100.9% during the fourth quarter. Mather Group LLC. now owns 661 shares of the medical equipment provider’s stock valued at $70,000 after purchasing an additional 332 shares in the last quarter. Institutional investors own 88.89% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on ZBH shares. Raymond James decreased their target price on Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating on the stock in a research report on Monday, October 14th. Needham & Company LLC reiterated a “hold” rating on shares of Zimmer Biomet in a research report on Wednesday, January 29th. Wells Fargo & Company boosted their price target on shares of Zimmer Biomet from $110.00 to $117.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 31st. Oppenheimer lowered their price objective on shares of Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating for the company in a research report on Tuesday, October 15th. Finally, Royal Bank of Canada boosted their target price on shares of Zimmer Biomet from $120.00 to $125.00 and gave the stock an “outperform” rating in a report on Monday, November 4th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $124.11.

Zimmer Biomet Trading Down 5.0 %

Shares of ZBH opened at $102.84 on Friday. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.36 and a quick ratio of 0.70. The firm has a market capitalization of $20.47 billion, a price-to-earnings ratio of 19.55, a PEG ratio of 1.88 and a beta of 1.02. The company has a 50-day moving average of $107.75 and a 200 day moving average of $108.20. Zimmer Biomet Holdings, Inc. has a 1-year low of $100.67 and a 1-year high of $133.90.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, beating analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. During the same quarter in the prior year, the business posted $2.20 EPS. On average, research analysts expect that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current year.

Zimmer Biomet Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Monday, December 30th were issued a dividend of $0.24 per share. The ex-dividend date was Monday, December 30th. This represents a $0.96 dividend on an annualized basis and a yield of 0.93%. Zimmer Biomet’s dividend payout ratio is currently 18.25%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.